Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Oncogene. 2022 May;41(21):2973-2983. doi: 10.1038/s41388-022-02305-x. Epub 2022 Apr 22.
Oncogene. 2022.
PMID: 35459782
Free PMC article.
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE, Wan X, Roth JS, Liewehr DJ, Sealover NE, Frye WJE, Kim A, Stauffer S, Perkins OL, Sun W, Isanogle KA, Robinson CM, James A, Awasthi P, Shankarappa P, Luo X, Lei H, Butcher D, Smith R, Edmondson EF, Chen JQ, Kedei N, Peer CJ, Shern JF, Figg WD, Chen L, Hall MD, Difilippantonio S, Barr FG, Kortum RL, Robey RW, Vaseva AV, Khan J, Yohe ME.
Hebron KE, et al.
Clin Cancer Res. 2023 Jan 17;29(2):472-487. doi: 10.1158/1078-0432.CCR-22-1646.
Clin Cancer Res. 2023.
PMID: 36322002
Free PMC article.
Item in Clipboard
Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR, Bondra K, Wang L, Sreenivas P, Zhao XR, Modi P, Vaseva AV, Houghton PJ, Ignatius MS.
Hensch NR, et al.
Mol Cancer Ther. 2023 Jan 3;22(1):123-134. doi: 10.1158/1535-7163.MCT-22-0310.
Mol Cancer Ther. 2023.
PMID: 36162055
Free PMC article.
Item in Clipboard
Cite
Cite